Open AccessReduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States
Author(s) -
Paschalis Vergidis,
Raymund R. Razonable,
L. Joseph Wheat,
Lynn L. Estes,
Angela M. Caliendo,
Lindsey R. Baden,
John R. Wingard,
John W. Baddley,
Maha Assi,
Steven J. Norris,
Pranatharthi Chandrasekar,
Ryan K. Shields,
Hồng Quân Nguyễn,
Alison G. Freifeld,
Richard Köhler,
Martin B. Kleiman,
Thomas J. Walsh,
Chadi A. Hage
Publication year - 2014
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00285-14
Subject(s) - galactomannan , immunoassay , piperacillin/tazobactam , aspergillus , piperacillin , tazobactam , medicine , microbiology and biotechnology , gastroenterology , immunology , aspergillosis , biology , antibiotics , antibody , bacteria , antibiotic resistance , genetics , imipenem , pseudomonas aeruginosa
Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) was positive. PTZ formulations commonly used in the United States today appear to be a rare cause for false-positive GM results.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom